PHI with Breast sarcoma surgery
How does this condition affect your private health insurance?
Mammary sarcoma is a rare and aggressive form of breast cancer, originating in the connective tissues rather than glandular cells. It accounts for less than 1% of all breast malignancies. The
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Typically several weeks to a few months from symptom onset to diagnosis and treatment.
Duration of Illness (Lifetime)
Can be a one-time event if successfully treated early; however, recurrence or metastasis can lead to years of chronic management.
Cost of Treatment (Initial)
High, ranging from tens of thousands to over one hundred thousand US dollars for diagnostics, surgery, hospital stay, and initial adjuvant therapies.
Cost of Treatment (Lifetime)
Potentially hundreds of thousands to millions of US dollars if recurrence, metastasis, or long-term complications require extensive, prolonged treatment and follow-up.
Mortality Rate
Significant, ranging from 20% to over 80% depending on tumor stage, grade, histology, and response to treatment.
Risk of Secondary Damages
High, including surgical complications (e.g., lymphedema, pain), psychological distress, body image issues, and side effects from chemotherapy or radiation therapy.
Probability of Full Recovery
Moderate, approximately 50-70% for early-stage, localized disease with clear surgical margins; significantly lower for advanced or metastatic cases.
Underlying Disease Risk
Low for directly co-occurring diseases, but certain genetic predispositions like Li-Fraumeni syndrome can increase the risk of developing sarcomas.